- Home
- PHAR vs BCX Comparison
PHAR vs BCX Comparison
Compare PHAR & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BCX
- Stock Information
- Founded
- PHAR 1988
- BCX 2011
- Country
- PHAR Netherlands
- BCX United States
- Employees
- PHAR N/A
- BCX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- PHAR Health Care
- BCX Finance
- Exchange
- PHAR Nasdaq
- BCX Nasdaq
- Market Cap
- PHAR 627.5M
- BCX 745.8M
- IPO Year
- PHAR N/A
- BCX N/A
- Fundamental
- Price
- PHAR $8.51
- BCX $8.72
- Analyst Decision
- PHAR Strong Buy
- BCX
- Analyst Count
- PHAR 3
- BCX 0
- Target Price
- PHAR $27.00
- BCX N/A
- AVG Volume (30 Days)
- PHAR 7.3K
- BCX 370.6K
- Earning Date
- PHAR 10-24-2024
- BCX 01-01-0001
- Dividend Yield
- PHAR N/A
- BCX 6.99%
- EPS Growth
- PHAR N/A
- BCX N/A
- EPS
- PHAR N/A
- BCX N/A
- Revenue
- PHAR $285,745,000.00
- BCX N/A
- Revenue This Year
- PHAR $20.89
- BCX N/A
- Revenue Next Year
- PHAR $11.15
- BCX N/A
- P/E Ratio
- PHAR N/A
- BCX N/A
- Revenue Growth
- PHAR 30.64
- BCX N/A
- 52 Week Low
- PHAR $6.65
- BCX $8.25
- 52 Week High
- PHAR $13.20
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- PHAR 53.32
- BCX 26.00
- Support Level
- PHAR $8.71
- BCX $8.71
- Resistance Level
- PHAR $9.59
- BCX $9.53
- Average True Range (ATR)
- PHAR 0.33
- BCX 0.15
- MACD
- PHAR 0.11
- BCX -0.06
- Stochastic Oscillator
- PHAR 51.03
- BCX 4.27
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.